Schizophreniform disorder

Summary

Schizophreniform disorder (MONDO:0001265) is a disease and 117 clinical trials. Top therapeutic interventions include olanzapine, raloxifene, and citalopram. A subtype of psychotic disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 117

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	schizophreniform disorder
Mondo ID	MONDO:0001265
DOID	DOID:11328
ICD-10-CM	F20.81
NCIT	C94376
SNOMED CT	88975006
UMLS	C0036358
MedGen	11336
Is cancer (heuristic)	no

Disease family

This is a subtype of psychotic disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › cognitive disorder › psychotic disorder › schizophreniform disorder

Related subtypes (7): alcoholic psychosis, delusional disorder, substance-induced psychosis, schizophrenia, methamphetamine-induced psychosis, schizoaffective disorder, postpartum psychosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 117.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	61
PHASE4	26
PHASE3	10
PHASE2	10
PHASE1	6
PHASE1/PHASE2	2
PHASE2/PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00246259	PHASE4	COMPLETED	A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis
NCT00314327	PHASE4	TERMINATED	Optimizing Response in Psychosis Study
NCT00337662	PHASE4	COMPLETED	Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia
NCT00361543	PHASE4	COMPLETED	Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT00465283	PHASE4	UNKNOWN	Donepezil Double Blind Trial for ECT Memory Disfunction
NCT00492349	PHASE4	COMPLETED	Varenicline Adjunctive Treatment in Schizophrenia
NCT00595504	PHASE4	COMPLETED	Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia
NCT00681629	PHASE4	TERMINATED	Schizophrenic Patients in Integrated Care
NCT00847600	PHASE4	COMPLETED	Pregnenolone Augmentation in the Treatment of Patients With Recent-Onset Schizophrenia
NCT01041274	PHASE4	COMPLETED	DECIFER: Depression and Citalopram In First Episode Recovery
NCT01082588	PHASE4	COMPLETED	Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia
NCT01248195	PHASE4	COMPLETED	Optimization of Treatment and Management of Schizophrenia in Europe
NCT01481883	PHASE4	COMPLETED	Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men?
NCT01855074	PHASE4	COMPLETED	An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders
NCT01913327	PHASE4	TERMINATED	Antipsychotic Effects on Brain Function in Schizophrenia
NCT02095938	PHASE4	UNKNOWN	Association of Amisulpride Response in Schizophrenia With Brain Image
NCT02137993	PHASE4	COMPLETED	Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia
NCT02949232	PHASE4	TERMINATED	Prednisolone Addition for Patients With Recent-onset Psychotic Disorder
NCT03061136	PHASE4	WITHDRAWN	Clonazepam Effects on Brain Oscillations and Cognition in Schizophrenia
NCT03559426	PHASE4	COMPLETED	Research Into Antipsychotic Discontinuation and Reduction Trial
NCT04004416	PHASE4	COMPLETED	Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis
NCT04113993	PHASE4	UNKNOWN	Bazedoxifene -Treatment for Women With Schizophrenia
NCT04203056	PHASE4	TERMINATED	Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode
NCT05974527	PHASE4	WITHDRAWN	Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department
NCT06041646	PHASE4	COMPLETED	Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
NCT07263022	PHASE3	NOT_YET_RECRUITING	Cognitive Strategies in Early Psychosis 2
NCT00419146	PHASE2/PHASE3	COMPLETED	Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants
NCT00421954	PHASE3	COMPLETED	Open-label Ziprasidone Study for Psychosis Treatment in Adolescents
NCT01999309	PHASE3	COMPLETED	Simvastatin Addition for Patients With Recent-onset Schizophrenia
NCT03043820	PHASE3	COMPLETED	Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder
NCT03187769	PHASE3	COMPLETED	Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder
NCT03201757	PHASE3	COMPLETED	Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831
NCT03848234	PHASE3	COMPLETED	Estradiol Patch as add-on to Antipsychotics in Patients With Schizophrenia, Schizoaffective or Schizophreniform Disorder
NCT04093518	PHASE3	UNKNOWN	Estradiol as add-on to Antipsychotics
NCT04268303	PHASE3	COMPLETED	Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
NCT05658510	PHASE3	COMPLETED	Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
NCT00206557	PHASE2	COMPLETED	The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot Study
NCT00206570	PHASE2	COMPLETED	Clinical Estradiol Trial in Women With Schizophrenia
NCT00357006	PHASE2	COMPLETED	A Definitive Estrogen Patch Study (ADEPT)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
OLANZAPINE	4	6
RALOXIFENE	4	6
CITALOPRAM	4	3
ZIPRASIDONE	4	3
AMISULPRIDE	4	2
LURASIDONE	4	2
MODAFINIL	4	2
VARENICLINE	4	2
AMANTADINE	4	1
ARIPIPRAZOLE	4	1
ARIPIPRAZOLE LAUROXIL	4	1
BAZEDOXIFENE ACETATE	4	1
BENZTROPINE	4	1
BETAHISTINE	4	1
CLONAZEPAM	4	1
DIPYRIDAMOLE	4	1
DONEPEZIL	4	1
ESCITALOPRAM	4	1
LORAZEPAM	4	1
METFORMIN	4	1
PRAVASTATIN	4	1
PREDNISOLONE	4	1
RAMELTEON	4	1
RISPERIDONE	4	1
SODIUM BENZOATE	4	1
TRYPTOPHAN	4	1
(D)-SERINE	3	1
LACTOSE, ANHYDROUS	3	1
OMEGA-3 FATTY ACIDS	3	1
PREGNENOLONE SUCCINATE	3	1